COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu
Trial record 3 of 1271 for:    LARS

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors (PASSILCORT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02749227
Recruitment Status : Active, not recruiting
First Posted : April 22, 2016
Last Update Posted : February 19, 2019
Information provided by (Responsible Party):
Pamela U. Freda, Columbia University

Brief Summary:
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin (POMC) levels will reduce plasma POMC levels and this will be associated with a reduction in pituitary tumor size. Pasireotide LAR 40 mg will be administered monthly. Baseline and monthly visits on therapy will monitor plasma levels of POMC, other pituitary function, safety labs, glucose tolerance, physical examination, and visual fields. Pituitary magnetic resonance imaging (MRI) will be done at baseline, 6 months and 12 months of therapy. The eligible patient population will consist of adult patients with known silent corticotroph pituitary tumors and elevated plasma levels of POMC.

Condition or disease Intervention/treatment Phase
Pituitary Tumor ACTH-producing Pituitary Tumour Drug: Pasireotide LAR Phase 2

Detailed Description:
Clinically non-functioning pituitary adenomas (CNFAs), the subtype of pituitary adenomas that does not appear to secrete biologically active hormone nor to have a characteristic clinical phenotype, are the most common type of pituitary macroadenoma at diagnosis. There is currently no option for medical therapy of CNFA, in general, or specifically of silent corticotroph tumors. Silent corticotroph tumors can range from being completely asymptomatic to becoming large and causing significant hypothalamic/pituitary dysfunction and visual symptoms, and most data support that this type of tumor has a more aggressive phenotype. Current therapy consists primarily of surgical removal of the tumor and for recurrent or residual tumors, repeated surgery and/or radiotherapy. In very aggressive tumors, chemotherapy has been tried with some success. Therefore, a need exists for a medical therapeutic option for the treatment of this tumor type. This project assesses this clinical need.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC
Actual Study Start Date : July 10, 2017
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : April 2020

Arm Intervention/treatment
Experimental: Pasireotide LAR Therapy
Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
Drug: Pasireotide LAR

Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.

The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.

Other Name: Signifor LAR

Primary Outcome Measures :
  1. Change in plasma Proopiomelanocortin (POMC) levels [ Time Frame: Baseline, 12 months ]
    This is to measure the effect of Pasireotide LAR (long-acting release) treatment.

Secondary Outcome Measures :
  1. Change in pituitary tumor volume [ Time Frame: Baseline, 12 months ]
    This is to measure the effect of Pasireotide LAR (long-acting release) treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Adults (males and females) with a diagnosis of a clinically nonfunctioning pituitary tumor of the silent corticotroph tumor type (i.e., positive adrenocorticotropin (ACTH) staining on immunohistochemical staining of the pituitary tumor obtained at surgery)
  2. Plasma POMC level > upper limit of normal
  3. Prior pituitary tumor surgery with residual or recurrent pituitary tumor visible on MRI scan that is ≥ 5 mm from the optic chiasm.
  4. Surgical resection of the pituitary adenoma must have occurred two or more months prior to enrollment
  5. If patients have undergone pituitary radiotherapy they must have completed their course of radiotherapy at least 2 months prior to study screening
  6. No prior somatostatin analog therapy
  7. No concurrent use of dopamine agonist therapy
  8. No active malignancy
  9. Stable pituitary hormone supplements (x 2 months) prior to baseline visit
  10. Sign and date an informed consent document indicating that the subject has been informed of and agrees to all pertinent aspects of the trial

Exclusion criteria:

Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study:

  1. Patients with Cushing's disease (biochemical evidence of hypercortisolism)
  2. Patients with compression of the optic chiasm causing any visual field defect that requires surgical intervention
  3. Diabetic patients with poor glycemic control as evidenced by HbA1c >8%
  4. Patients who are hypothyroid or adrenally insufficient and not on adequate replacement therapy
  5. Patients with symptomatic cholelithiasis and acute or chronic pancreatitis
  6. Patients with risk factors for torsade de pointes, i.e., patients with a baseline QTcF (Fridericia's Correction Formula value) >450 ms in males, and >460 ms in females
  7. Hypokalaemia, hypomagnesaemia, uncontrolled hypothyroidism, family history of long QT syndrome or concomitant medications with known risk of Torsades de pointes (TdP). Drugs with possible risk of TdP should be avoided whenever feasible
  8. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute myocardial infarction (MI) less than one year prior to study entry or clinically significant impairment in cardiovascular function
  9. Concomitant disease(s) that could prolong the QT interval such as autonomic neuropathy (caused by diabetes or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
  10. Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 2.0 X upper limit of normal (ULN), serum bilirubin >2.0 X ULN
  11. Presence of Hepatitis B surface antigen (HbsAg) or Hepatitis C antibody test (anti-HCV)
  12. Patients with serum creatinine >2.0 X ULN
  13. Patients with white blood cell (WBC) count <3 X 109/L; Hb 90% < lower limit of normal (LLN); platelet (PLT) count <100 X 109/L
  14. Patients with the presence of active or suspected acute or chronic uncontrolled infection
  15. Patients who have undergone major surgery/surgical therapy for any cause within 4 weeks prior screening
  16. Patients with abnormal coagulation (PT and/or activated partial thromboplastin time (APTT) elevated by 30% above normal limits) or patients receiving anticoagulants that affect PT (prothrombin time) or APTT (activated partial thromboplastin time)
  17. History of syncope or family history of idiopathic sudden death
  18. History of immunocompromise, including a positive HIV test result (ELISA and Western blot)
  19. Sexually active males unless they use a condom during intercourse while taking drug and for 3 months following last dose of pasireotide and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid
  20. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
  21. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and 3 months following last dose of pasireotide. Highly effective contraception methods include:

    • Total abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject
    • Combination of any two of the following (a+b or a+c, or b+c):

      1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
      2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
      3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

        • In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
        • Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02749227

Layout table for location information
United States, New York
Neuroendocrine Unit and Pituitary Center, Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Layout table for investigator information
Principal Investigator: Pamela Freda, MD Columbia University
Layout table for additonal information
Responsible Party: Pamela U. Freda, Professor of Medicine at the Columbia University Medical Center, Dept of Medicine Endocrinology, Columbia University Identifier: NCT02749227    
Other Study ID Numbers: AAAQ6255
CSOM230GUS44T ( Other Identifier: Novartis )
First Posted: April 22, 2016    Key Record Dates
Last Update Posted: February 19, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pamela U. Freda, Columbia University:
Clinically non-functioning pituitary adenomas (CNFAs)
silent corticotroph adenomas
Additional relevant MeSH terms:
Layout table for MeSH terms
Pituitary Neoplasms
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs